$HALO News
Last published 5d ago
- 5d agoHALOHalozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029PR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty...
- 5d agoHALOU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck CancerPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S....
- 6d agoHALOHALOZYME THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoHALOHalozyme to Report Third Quarter 2026 Financial and Operating ResultsPR NewswireSAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5,
- 1mo agoHALOHalozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has...
- 1mo agoHALOHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license...
- 1mo agoHALOHalozyme Announces Appointment of Jim Daly to its Board of DirectorsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of...
- 1mo agoHALOHalozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1....
- 1mo agoHALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033PR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and...
- 1mo agoHALOHalozyme - 1774258 - HALOZYME THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Larmond, head of US Mid-Cap Biotech Equity Research here at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, I'll make you aware of some i
- 2mo agoHALOWells Fargo 21st Annual Healthcare Conference - HALOZYME THERAPEUTICS INCEarnings Call TranscriptsThank you very much for joining us for this afternoon's session today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts at Wells Fargo, and I'm joined by, once again, with Helen Tolley, the CEO of Helo
- 2mo agoHALOHalozyme to Participate at Upcoming Investor ConferencesPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren...
- 2mo agoHALOHalozyme Appoints Dannielle Appelhans to its Board of DirectorsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans...
- 3mo agoHALOHALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter...
- 3mo agoHALOHalozyme to Report Second Quarter 2026 Financial and Operating ResultsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on...
- 3mo agoHALOINCYHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license...
- 4mo agoHALOHalozyme Appoints David Ramsay as President Drug DeliveryPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery,...
- 4mo agoHALOHalozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029PR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue...
- 6mo agoHALOHalozyme 1Q 2026 Financial and Operating ResultsHALOZYME THERAPEUTICS INCEarnings Call TranscriptsGood afternoon. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to Halazime's first quarter 2026 Financial and Operating Results Conference Call. Please no
- 6mo agoHALOHALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCEPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter...
- 6mo agoHALOHalozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology TargetsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license...
- 6mo agoHALOORKAHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's...
- 6mo agoHALOHalozyme to Report First Quarter 2026 Financial and Operating ResultsPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on...
- 6mo agoHALOHalozyme Appoints Darren Snellgrove as Chief Financial OfficerPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial...
- 7mo agoHALOHalozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc.,...
- 8mo agoHALOHalozyme Appoints David Ramsay as Interim Chief Financial OfficerPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial ...
- 8mo agoHALOU.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple MyelomaPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug...
- 8mo agoHALOHalozyme to Participate in Upcoming Investor ConferencesPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to ...
- 8mo agoHALOHALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCEPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and...
- 9mo agoHALOHalozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating ResultsPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating ...
- 9mo agoHALOHalozyme Investor Conference Call - HALOZYME THERAPEUTICS INCEarnings Call TranscriptsGood morning. My name is Eric and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's Investor Conference Call. After the speaker's remarks, there will be a question and
- 9mo agoHALOHalozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial GuidancePR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited...
- 9mo agoHALOHalozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business UpdatePR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at...
- 10mo agoHALOHalozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®PR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with...
- 10mo agoHALOSKYEHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityGlobeNewswireSAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Skye Bioscience, Inc. (NASDAQ:SKYE) today announced the companies entered into a non-exclusive global collaboration and license
- 10mo agoHALOSKYEHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global ...
- 10mo agoHALOU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung CancerPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug...
- 11mo agoONCYAIMAVBPMRUS+1Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR NewswireUSANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination...
- 11mo agoHALOJim Lang Elected to Halozyme's Board of DirectorsPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
- 11mo agoHALOHalozyme Wins Preliminary Injunction Against Merck's Keytruda SC in GermanyPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction...
- 11mo agoHALOHalozyme to Participate in the 8th Annual Evercore Healthcare ConferencePR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present...
- 11mo agoHALOHalozyme, Inc. et al. vs Merck Sharp & Dohme LLC - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 11mo agoHALOHalozyme, Inc. et al. vs Merck Sharp & Dohme LLC - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 11mo agoHALOHalozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug DeliveryPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc....
- 11mo agoMRUSHALOMerus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of PetosemtamabPR NewswireMerus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates...
- 12mo agoHALOHalozyme, Inc. et al. vs Merck Sharp & Dohme LLC - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoHALOFDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple MyelomaPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA)...
- 1y agoHALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032PR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of...
- 1y agoHALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032PR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and...
- 1y agoHALOHALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTSPR NewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter...